Stocks · News reference
Turn Therapeutics Inc. is scheduled to participate in a virtual fireside chat hosted by BTIG to discuss the development program for its lead therapeutic candidate, GX-03.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Turn Therapeutics Inc. announced that its GX-03 therapy has been recognized as the 'Developmental Immunology Solution of the Year' in the 2026 BioTech Breakthrough Awards.
Analysts upgraded SAFE, CNOB, LMT and more.
Filed: 2026-10-07 AccNo: 0001213900-26-107329 Size: 23 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Analysts initiated coverage: ARES Overweight, $150; MGEE Neutral, $76; TTRX Buy, $24; QNCX Buy, $70; EFSC Buy, $70.
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and announces Price Target of $24.
WBB Securities analyst Karen Sterling downgrades Turn Therapeutics (NASDAQ:TTRX) from Hold to Sell and announces $10 price target.